Unknown

Dataset Information

Population Pharmacokinetic Modeling of Lucitanib in Patients with Advanced Cancer.


ABSTRACT:

Background

Lucitanib is an oral, potent, selective inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1‒3, fibroblast growth factor receptors 1‒3, and platelet-derived growth factor receptors alpha/beta.

Objective

We aimed to develop a population pharmacokinetics (PopPK) model for lucitanib in patients with advanced cancers.

Methods

PopPK analyses were based on intensive and sparse oral pharmacokinetic data from 5 phase 1/2 clinical studies of lucitanib in a total of 403 patients with advanced cancers. Lucitanib was administered at 5‒30 mg daily doses as 1 of 2 immediate-release oral formulations: a film-coated tablet or a hard gelatin capsule.

Results

Lucitanib pharmacokinetics were best described by a 2-compartment model

SUBMITTER: Liao M 

PROVIDER: S-EPMC9399017 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature